Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model
- 15 March 2010
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 79 (6), 880-887
- https://doi.org/10.1016/j.bcp.2009.10.025
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Quantitative Profiling Method for Oxylipin Metabolome by Liquid Chromatography Electrospray Ionization Tandem Mass SpectrometryAnalytical Chemistry, 2009
- Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivoMolecular Cancer Therapeutics, 2009
- Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammationBritish Journal of Pharmacology, 2009
- Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto–Kakizaki ratsClinical Science, 2008
- Orally Bioavailable Potent Soluble Epoxide Hydrolase InhibitorsJournal of Medicinal Chemistry, 2007
- Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted MiceOnline Journal of Public Health Informatics, 2007
- Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injuryProstaglandins & Other Lipid Mediators, 2007
- Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs)Prostaglandins & Other Lipid Mediators, 2007
- Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2006
- Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2006